Arena's obesity drug gets support from FDA panel

05/10/2012 | Wall Street Journal, The

An FDA advisory committee voted 18-4 to support approval of Arena Pharmaceuticals' obesity drug lorcaserin. The company said 38% of patients treated with lorcaserin lost at least 5% of their weight in a year, compared with 16% of patients in the placebo group.

View Full Article in:

Wall Street Journal, The

Published in Briefs: